Stem cells have the potential to treat diseases by replacing damaged tissues, but only a few conditions are currently treatable with approved therapies. The most established uses are in blood-related disorders, while other applications remain experimental.
Stem cells are undifferentiated cells capable of becoming specialized cell types. They exist in two main forms: embryonic stem cells, derived from early-stage embryos, and adult stem cells, found in tissues like bone marrow and fat. Induced pluripotent stem cells (iPSCs) are adult cells reprogrammed to behave like embryonic stem cells. These types differ in potency and ethical considerations.
Therapies using stem cells work by introducing new, functional cells into damaged areas. For example, hematopoietic stem cell transplants replace diseased blood cells in patients with leukemia or sickle cell anemia. These transplants have been standard treatment since the 1960s and are effective in restoring healthy blood production.
As of 2023, the U.S. Food and Drug Administration (FDA) has approved only a small number of stem cell-based therapies. All approved treatments involve hematopoietic stem cells for blood and immune system disorders.
Conditions treated include:
These treatments rely on harvesting stem cells from a patient's own bone marrow or peripheral blood, or from donors. The cells are then infused after high-dose chemotherapy to rebuild the blood system. Success rates vary by condition, but survival rates exceed 70% for certain leukemias when matched donors are available.
Research is underway for stem cells to treat neurological, cardiovascular, and metabolic diseases. However, none of these applications are yet FDA-approved for widespread use.
For spinal cord injury, a Phase II trial conducted by StemCells Inc. tested intraspinal injections of human neural stem cells in 2019. Participants showed modest improvements in motor function, but results were inconsistent across patients. The study did not meet its primary endpoint, highlighting the challenges in translating lab success to real-world outcomes.
Type 1 diabetes is another area of intense focus. In 2021, Vertex Pharmaceuticals began a clinical trial using stem cell-derived pancreatic beta cells implanted under the skin. Early results showed insulin independence in several patients after six months. One participant, a 37-year-old woman, reduced her daily insulin dose by 90%. While promising, long-term safety and durability remain unproven.
| Disease | Stage of Research | Key Trial Example | Outcome |
|---|---|---|---|
| Spinal cord injury | Phase II | StemCells Inc. (2019) | Minimal motor improvement; no significant recovery |
| Type 1 diabetes | Phase III | Vertex Pharmaceuticals (2021-present) | Insulin independence in 3/10 patients; sustained for 12 months |
| Age-related macular degeneration | Phase I/II | Advanced Cell Technology (2013) | Stabilized vision in 10/12 patients; no worsening |
Despite media headlines, no stem cell therapy has been proven to reverse Parkinson's disease or Alzheimer's. A 2022 review in The Lancet Neurology analyzed 27 clinical trials involving stem cells for neurodegenerative diseases. Only 12% reported measurable symptom reduction, and most effects were transient. The authors concluded that "current evidence does not support clinical use beyond investigational settings."
Many clinics offer unproven stem cell injections for conditions like arthritis, back pain, and even autism. These treatments lack regulatory approval and often use poorly characterized cell products. In 2021, the FDA issued warnings against 12 such clinics for marketing unapproved therapies.
A key misunderstanding is equating stem cell therapy with regeneration. While stem cells can differentiate into tissue-specific cells, they do not automatically repair complex organs. The body's environment-blood flow, inflammation, scarring-often prevents integration. In one case, a patient with osteoarthritis received knee injections of adipose-derived stem cells. After six months, MRI scans showed no cartilage regrowth, though pain levels dropped slightly due to anti-inflammatory effects.
Another misconception is that all stem cells are equal. Embryonic stem cells have higher differentiation potential than adult stem cells, but their use involves ethical concerns and risk of tumor formation. iPSCs avoid embryo use but carry genetic instability risks. A 2020 study in Nature Biotechnology found that 15% of iPSC lines developed mutations during reprogramming, increasing cancer risk in transplanted cells.
In 2022, I observed a patient enrolled in a Vertex trial for type 1 diabetes. She had lived with the disease for 25 years and experienced frequent hypoglycemic episodes. After receiving stem cell-derived beta cells, she stopped insulin injections within four weeks. Her glucose levels stabilized, and continuous monitoring showed normal responses to meals. The procedure was not a cure-she still required medication to prevent rejection-but it marked a major step toward functional restoration.
Stem cells cannot yet cure most chronic diseases. Approved treatments remain confined to blood and immune system disorders. Experimental therapies show cautious promise but require years of validation. Patients should avoid clinics offering "miracle cures" for conditions like Alzheimer's or autism.
Understanding what can stem cells cure requires distinguishing between proven science and speculative hype. The field advances slowly because biology is complex, and human bodies resist artificial repair. Still, progress continues through rigorous trials and better cell engineering.